The borrowing extends Dyne's cash runway ahead of clinical catalysts, but the IP collateral and covenant structure warrant monitoring. With $200M drawn and $200M additional capacity tied to milestones/lender approval, the trajectory of the pipeline (muscle disease programs) determines future drawdowns. Watch for next clinical data readouts and any exercise of the $75M discretionary tranche — discretionary lender approval could signal credit concern if DYN delays.
Price Chart
Executive Summary
Dyne Therapeutics expanded its Hercules Capital debt facility to $400M via a Second Amendment, borrowing an additional $50M on closing. The amendment adds two new $50M tranches and increases the final tranche by $25M, while reducing the minimum cash covenant from 60% to 40% of outstanding obligations and pushing the testing date from January 2027 to July 2027 (extendable to 2028). Outstanding debt post-borrowing is $200M, with up to $200M in additional undrawn tranches available upon milestones or lender approval. The move extends cash runway for a pre-revenue biotech with a $3.0B market cap and 85% analyst buy rating, but adds leverage and secured IP collateral — net neutral for the credit story.
Key Financial Metrics
Key Facts
- Debt facility expanded to an aggregate of up to $400.0 million (from $325M prior structure)
- Second Amendment added two $50M tranches and increased the final tranche by $25M
- Borrowed $50.0 million on the Amendment Closing Date (June 16, 2026)
- Outstanding principal after borrowing: $200.0 million
- Undrawn capacity: $125M (milestone-based) + $75M (lender discretion) = up to $200M
- Minimum cash covenant reduced from 60% to 40% of outstanding obligations, tested only if market cap < $1.65B
- Initial cash covenant testing date moved from Jan 1, 2027 to Jul 1, 2027 (extendable to Jul 1, 2028)
- Interest rate: WSJ Prime + 2.45% with 7.50% floor; interest-only until Jul 1, 2029 (extendable to maturity)
- Maturity date: July 1, 2030
- First-priority security interest on substantially all assets, including IP
Financial Impact
Added $50M cash to balance sheet with $200M drawn total and $200M additional accordion; interest cost ~10.0% (Prime ~7.5% + 2.45%). No revenue or earnings impact reported.
Risk Factors
- Interest rate exposure: floating rate with 7.50% floor could increase costs if Prime rises
- IP collateral: first-priority security interest on all IP means lenders have edge in distress
- Milestone dependence: $125M of undrawn tranches requires clinical/regulatory/commercial milestones — delays could limit access to capital
- Pandemic/clinical risk: pre-revenue biotech with no approved products; stock price volatility could trigger minimum cash covenant (tested only if mkt cap < $1.65B)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001818794-26-000003 |
| Document: 0001818794-26-000003-index-headers.html | 0001818794-26-000003 |
| Document: 0001818794-26-000003-index.html | 0001818794-26-000003 |
| Document: 0001818794-26-000003.txt | 0001818794-26-000003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access